Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11844785 | 0.79 | GPR84 (0.42) | GPR84CA2MAPK1 | |
| SCHEMBL20141889 | 0.79 | GPR84 (0.42) | GPR84FFAR4FFAR1CA2MAPK1 | |
| SCHEMBL499960 | 0.75 | POLB (0.40) | GPR84MAPK1 | |
| SCHEMBL6214649 | 0.73 | HTT (0.38) | GPR84CA2MAPK1 | |
| SCHEMBL5140381 | 0.70 | DPP7 (0.37) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL21140634 | 0.70 | FDPS (0.35) | GPR84FFAR1 | |
| SCHEMBL19942664 | 0.70 | FDPS (0.35) | GPR84FFAR1 | |
| SCHEMBL20988033 | 0.68 | DPP4 (0.37) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL10611419 | 0.68 | DPP4 (0.33) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL500539 | 0.66 | KDM4E (0.44) | DPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545517-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | Merck Frosst Canada & Co. (CA) | 2005-06-29 | — | — | EP | claimed |
| WO-2004019938-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2004-03-11 | — | — | WO | claimed |
| EP-1545517-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | Merck Frosst Canada & Co. (CA) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019938-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2004-03-11 | — | — | WO | disclosed |